Molekulare kardiovaskuläre Bildgebung

Zusammenfassung

In der kardiovaskulären Diagnostik bestehen trotz intensiver und langjähriger Forschung im Bereich der bildgebenden Diagnostik nahezu unverändert große Herausforderungen. Im Speziellen sind dies Fragestellungen im Zusammenhang mit der Diagnostik einer vermuteten oder bestehenden koronaren Herzkrankheit oder deren Folgen (Myokardinfarkt, Herzinsuffizienz). Neben morphologisch orientierten bildgebenden Verfahren, haben bereits heute funktionelle Verfahren einen diagnostischen Stellenwert, hingegen sind molekulare Bildgebungsverfahren noch in der Entwicklung. Dieser Beitrag gibt einen Überblick der klinisch-diagnostischen Herausforderungen in der kardiovaskulären Medizin sowie über Lösungsansätze durch neu zu entwickelnde molekulare Bildgebungsmodalitäten.

Abstract

Although huge and long-lasting research efforts have been spent on the development of new diagnostic techniques investigating cardiovascular diseases, still fundamental challenges exist; the main challenge being the diagnosis of a suspected or known coronary artery disease or its consequences (myocardial infarction, heart failure etc.). Beside morphological techniques, functional imaging modalities are available in clinical diagnostic algorithms, whereas molecular cardiovascular imaging techniques are still under development. This review summarizes clinical-diagnostical challenges of modern cardiovascular medicine as well as the potential of new molecular imaging techniques to face these.

molekulare Bildgebung - kardiovaskuläre Erkrankungen - PET - SPECT - Plaque - Arteriosklerose - Herzrhythmusstörungen

molecular imaging - cardiovascular diseases - PET - SPECT - plaque - atherosclerosis - tachyarrhythmias

Literatur

• 1 Berman D S, Hachamovitch R, Shaw L J, Friedman J D, Hayes S W, Thomson L E, Fieno D S, Germano G, Wong N D, Kang X, Rozanski A. Roles of nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance: Noninvasive risk stratification and a conceptual framework for the selection of noninvasive imaging tests in patients with known or suspected coronary artery disease.  J Nucl Med. 2006;  47 1107-1118
• 2 Isbell D C, Kramer C M. Magnetic resonance for the assessment of myocardial viability.  Curr Opin Cardiol. 2006;  21 469-472
• 3 Slart R H, Bax J J, van Veldhuisen D J, van der Wall E E, Dierckx R A, Jager P L. Imaging techniques in nuclear cardiology for the assessment of myocardial viability.  Int J Cardiovasc Imaging. 2006;  22 63-80
• 4 Schwaiger M, Ziegler S, Nekolla S G. PET/CT: challenge for nuclear cardiology.  J Nucl Med. 2005;  46 1664-1678
• 5 Schäfers K P, Dawood M, Lang N, Büther F, Schäfers M, Schober O. Motion correction in PET/CT.  Nuklearmedizin. 2005;  44 46-50
• 6 Jaffer F A, Weissleder R. Seeing within: molecular imaging of the cardiovascular system.  Circ Res. 2004;  94 433-445
• 7 Behm C Z, Lindner J R. Cellular and molecular imaging with targeted contrast ultrasound.  Ultrasound Q. 2006;  22 67-72
• 8 Falk E, Shah P K, Fuster V. Coronary plaque disruption.  Circulation. 1995;  92 657-671
• 9 Vanzetto G, Ormezzano O, Fagret D, Comet M, Denis B, Machecourt J. Long-term additive prognostic value of thallium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: study in 1 137 patients with 6-year follow-up.  Circulation. 1999;  100 1521-1527
• 10 Greenland P, LaBree L, Azen S P, Doherty T M, Detrano R C. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals.  JAMA. 2004;  291 210-215
• 11 Rudd J H, Warbourton E A, Fryer T D, Jones H A, Clark J C, Antoun N, Johnstrom P, Davenport A P, Kirkpatrick P J, Arch B N, Pickard J D, Weissberg P L. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography.  Circulation. 2002;  105 2708-2711
• 12 Breyholz H J, Schäfers M, Wagner S, Höltke C, Faust A, Rabeneck H, Levkau B, Schober O, Kopka K. C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.  J Med Chem. 2005;  48 3400-3409
• 13 Kopka K, Breyholz H J, Wagner S, Law M P, Riemann B, Schroer S, Trub M, Guilbert B, Levkau B, Schober O, Schafers M. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo.  Nucl Med Biol. 2004;  2 257-267
• 14 Bremer C, Tung C H, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition.  Nat Med. 2001;  7 743-748
• 15 Schäfers M, Riemann B, Kopka K, Breyholz H, Wagner S, Schäfers K P, Law M P, Schober O, Levkau B. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo.  Circulation. 2004;  109 2554-2559
• 16 Boersma H H, Kietselaer B L, Stolk L M, Bennaghmouch A, Hofstra L, Narula J, Heidendal G A, Reutelingsperger C P. Past, present, and future of annexin A5: from protein discovery to clinical applications.  J Nucl Med. 2005;  46 2035-2050
• 17 Kopka K, Faust A, Keul P, Wagner S, Breyholz H J, Höltke C, Schober O, Schäfers M, Levkau B. Non-invasive imaging of caspase activity in apoptosis: Potential of 5-pyrrolidinylsulfonyl isatins as novel molecular tracers.  J Med Chem. 2006;  ,  in press
• 18 Schäfers M, Dutka D, Rhodes C G, Lammertsma A A, Hermansen F, Schober O, Camici P G. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy.  Circ Res. 1998;  82 57-62
• 19 Wichter T, Schäfers M, Rhodes C G, Borggrefe M, Lerch H, Lammertsma A A, Hermansen F, Schober O, Breithardt G, Camici P G. Abnormalities of cardiac sympathetic innervation in arrhythmogenic right ventricular cardiomyopathy: quantitative assessment of presynaptic norepinephrine reuptake and postsynaptic beta-adrenergic receptor density with positron emission tomography.  Circulation. 2000;  101 1552-1558
• 20 Schäfers M, Lerch H, Wichter T, Rhodes C G, Lammertsma A A, Borggrefe M, Hermansen F, Schober O, Breithardt G, Camici P G. Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia.  J Am Coll Cardiol. 1998;  32 181-186
• 21 Kies P, Wichter T, Schäfers M, Paul M, Schäfers K P, Eckardt L, Stegger L, Schulze-Bahr E, Rimoldi O, Breithardt G, Schober O, Camici P G. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome.  Circulation. 2004;  110 3017-3022
• 22 Schwartz P J, Priori S G, Spazzolini C, Moss A J, Vincent G M, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating M T, Towbin J A, Beggs A H, Brink P, Wilde A A, Toivonen L, Zareba W, Robinson J L, Timothy K W, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann M H, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.  Circulation. 2001;  103 89-95
• 23 Delahaye N, Le Guludec D, Dinanian S, Delforge J, Slama M S, Sarda L, Dolle F, Mzabi H, Samuel D, Adams D, Syrota A, Merlet P. Myocardial muscarinic receptor upregulation and normal response to isoproterenol in denervated hearts by familial amyloid polyneuropathy.  Circulation. 2001;  104 2911-2916
• 24 Anastasiou-Nana M I, Terrovitis J V, Athanasoulis T, Karaloizos L, Geramoutsos A, Pappa L, Tsagalou E P, Efentakis S, Nanas J N. Prognostic value of iodine-123-metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.  Am J Cardiol. 2005;  96 427-431
• 25 Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobrnzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure.  Eur J Nucl Med Mol Imaging. 2004;  32 186-194